Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Non-Randomized, Open-Label, Parallel-Group Study to Investigate the Effects of Coadministration of the Proton Pump Inhibitor Omeprazole or the P-gp/BCRP Inhibitor Cyclosporine on the Pharmacokinetics, Safety, and Tolerability of Velzatinib in Healthy Participants

NCT07862114 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT07862114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07862114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Non-Randomized, Open-Label, Parallel-Group Study to Investigate the Effects of Coadministration of the Proton Pump Inhibitor Omeprazole or the P-gp/BCRP Inhibitor Cyclosporine on the Pharmacokinetics, Safety, and Tolerability of Velzatinib in Healthy Participants
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 16, 2026
Completion date
January 12, 2027
Enrollment
36 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal neoplasms, healthy participants